[en] Two new analogues of CDDO-Imidazolide (CDDO-Im), namely 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole ("CDDO-2P-Im") and 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-3-yl)-1H-imidazole ("CDDO-3P-Im") have been synthesized and tested for their potential use as chemopreventive drugs. At nanomolar concentrations, they were equipotent to CDDO-Im for inducing differentiation and apoptosis in U937 leukemia cells. As inflammation and oxidative stress contribute to carcinogenesis, we also assessed their cytoprotective potential. The new compounds suppressed inducible nitric oxide synthase (iNOS) expression in RAW264.7 macrophage-like cells and significantly elevated heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo. Most importantly, pharmacokinetic studies performed in vitro in human plasma and in vivo showed that each new analogue was more stable than CDDO-Im. Much higher concentrations of the new derivatives were found in mouse liver, lung, pancreas and kidney after gavage in contrast to CDDO-Im. Because of their better bioavailability and their excellent anti-inflammatory profile in vitro, CDDO-2P-Im and CDDO-3P-Im were tested for prevention in a highly relevant mouse lung cancer model, in which A/J mice develop lung carcinomas after injection of vinyl carbamate, a potent carcinogen. CDDO-2P-Im and CDDO-3P-Im were as effective as CDDO-Im for reducing the size and the severity of the lung tumors.
A.E. Place, N. Suh, C.R. Williams, R. Risingsong, T. Honda, Y. Honda, G.W. Gribble, L.M. Leesnitzer, J.B. Stimmel, T.M. Willson, E. Rosen, and M.B. Sporn The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo Clin. Cancer Res. 9 2003 2798 2806
K.T. Liby, and M.B. Sporn Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease Pharmacol. Rev. 64 2012 972 1003
K. Liby, T. Hock, M.M. Yore, N. Suh, A.E. Place, R. Risingsong, C.R. Williams, D.B. Royce, T. Honda, Y. Honda, G.W. Gribble, N. Hill-Kapturczak, A. Agarwal, and M.B. Sporn The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling Cancer Res. 65 2005 4789 4798
M.S. Yates, M. Tauchi, F. Katsuoka, K.C. Flanders, K.T. Liby, T. Honda, G.W. Gribble, D.A. Johnson, J.A. Johnson, N.C. Burton, T.R. Guilarte, M. Yamamoto, M.B. Sporn, and T.W. Kensler Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes Mol. Cancer Ther. 6 2007 154 162
M.S. Yates, Q.T. Tran, P.M. Dolan, W.O. Osburn, S. Shin, C.C. McCulloch, J.B. Silkworth, K. Taguchi, M. Yamamoto, C.R. Williams, K.T. Liby, M.B. Sporn, T.R. Sutter, and T.W. Kensler Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice Carcinogenesis 30 2009 1024 1031
K. Liby, N. Voong, C.R. Williams, R. Risingsong, D.B. Royce, T. Honda, G.W. Gribble, M.B. Sporn, and J.J. Letterio The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells Clin. Cancer Res. 12 2006 4288 4293
M.M. Yore, A.N. Kettenbach, M.B. Sporn, S.A. Gerber, and K.T. Liby Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR PLoS One 6 2011 e22862
M.S. Yates, M.K. Kwak, P.A. Egner, J.D. Groopman, S. Bodreddigari, T.R. Sutter, K.J. Baumgartner, B.D. Roebuck, K.T. Liby, M.M. Yore, T. Honda, G.W. Gribble, M.B. Sporn, and T.W. Kensler Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole Cancer Res. 66 2006 2488 2494
J.Y. So, J.J. Lin, J. Wahler, K.T. Liby, M.B. Sporn, and N. Suh A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer PLoS One 9 2014 e107616
N.M. Johnson, P.A. Egner, V.K. Baxter, M.B. Sporn, R.S. Wible, T.R. Sutter, J.D. Groopman, T.W. Kensler, and B.D. Roebuck Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold Cancer Prev. Res. 7 2014 658 665
T. Honda, Y. Honda, F.G. Favaloro Jr., G.W. Gribble, N. Suh, A.E. Place, M.H. Rendi, and M.B. Sporn A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production Bioorg. Med. Chem. Lett. 12 2002 1027 1030
K.M. Lancaster, J.B. Gerken, A.C. Durrell, J.H. Palmer, and H.B. Gray Electronic structures, photophysical properties, and electrochemistry of ruthenium(II)(bpy)(2) pyridylimidazole complexes Coord. Chem. Rev. 254 2010 1803 1811
H. Yamadaand, and T. Okamoto Formamide reactions. I, Reaction with alkyl halides, alkyl formates and alcohols (author's transl.) Yakugaku Zasshi: J. Pharm. Soc. Jpn. 95 1975 487 492
K. Liby, R. Risingsong, D.B. Royce, C.R. Williams, T. Ma, M.M. Yore, and M.B. Sporn Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice Cancer Prev. Res. 2 2009 1050 1058
N. Suh, T. Honda, H.J. Finlay, A. Barchowsky, C. Williams, N.E. Benoit, Q.W. Xie, C. Nathan, G.W. Gribble, and M.B. Sporn Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages Cancer Res. 58 1998 717 723
T.D. Schmittgenand, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nature Protoc. 3 2008 1101 1108
H.J. Prochaskaand, and A.B. Santamaria Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers Anal. Biochem. 169 1988 328 336
K. Liby, D.B. Royce, C.R. Williams, R. Risingsong, M.M. Yore, T. Honda, G.W. Gribble, E. Dmitrovsky, T.A. Sporn, and M.B. Sporn The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice Cancer Res. 67 2007 2414 2419
C. Nathanand, and A. Ding Nonresolving inflammation Cell 140 2010 871 882
K.D. Kroncke, K. Fehsel, and V. Kolb-Bachofen Inducible nitric oxide synthase in human diseases Clin. Exp. Immun. 113 1998 147 156
R. Zamora, Y. Vodovotz, and T.R. Billiar Inducible nitric oxide synthase and inflammatory diseases Mol. Med. 6 2000 347 373
M. Lechner, P. Lirk, and J. Rieder Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin Sem. Cancer Biol. 15 2005 277 289
K.T. Liby, D.B. Royce, R. Risingsong, C.R. Williams, A. Maitra, R.H. Hruban, and M.B. Sporn Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer Cancer Prev. Res. 3 2010 1427 1434
C. To, C.S. Ringelberg, D.B. Royce, C.R. Williams, R. Risingsong, M.B. Sporn, and K.T. Liby Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis Carcinogenesis 36 2015 769 781
M. Liu, N.M. Reddy, E.M. Higbee, H.R. Potteti, S. Noel, L. Racusen, T.W. Kensler, M.B. Sporn, S.P. Reddy, and H. Rabb The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice Kidney Int. 85 2014 134 141
P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, E.B. Grossman, M. Krauth, S. Ruiz, P. Audhya, H. Christ-Schmidt, J. Wittes, and D.G. Warnock BEAM Study Investigators, Bardoxolone methyl and kidney function in CKD with type 2 diabetes N. Engl. J. Med. 365 2011 327 333
J. Alam, D. Stewart, C. Touchard, S. Boinapally, A.M. Choi, and J.L. Cook Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 274 1999 26071 26078
T.W. Kensler, N. Wakabayashi, and S. Biswal Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Ann. Rev. Pharmacol. Toxicol. 47 2007 89 116
A.T. Dinkova-Kostovaand, and P. Talalay NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector Arch. Biochem. Biophys. 501 2010 116 123
X. Yuand, and T. Kensler Nrf2 as a target for cancer chemoprevention Mutat. Res. 591 2005 93 102
B.S. Cornblatt, L. Ye, A.T. Dinkova-Kostova, M. Erb, J.W. Fahey, N.K. Singh, M.S. Chen, T. Stierer, E. Garrett-Mayer, P. Argani, N.E. Davidson, P. Talalay, T.W. Kensler, and K. Visvanathan Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast Carcinogenesis 28 2007 1485 1490
S.S. Hecht, F. Kassie, and D.K. Hatsukami Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers Nat. Rev. Cancer 9 2009 476 488
H. Lu, W. Ouyang, and C. Huang Inflammation, a key event in cancer development Mol. Cancer Res. 4 2006 221 233
M.L. Hyer, R. Shi, M. Krajewska, C. Meyer, I.V. Lebedeva, P.B. Fisher, and J.C. Reed Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer Cancer Res. 68 2008 2927 2933
A. Bishayee, S. Ahmed, N. Brankov, and M. Perloff Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer Front. Biosci. 16 2011 980 996
F. Zhang, S. Wang, M. Zhang, Z. Weng, P. Li, Y. Gan, L. Zhang, G. Cao, Y. Gao, R.K. Leak, M.B. Sporn, and J. Chen Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury Stroke J. Cerebral Circ. 43 2012 1390 1397
T.E. Sussan, T. Rangasamy, D.J. Blake, D. Malhotra, H. El-Haddad, D. Bedja, M.S. Yates, P. Kombairaju, M. Yamamoto, K.T. Liby, M.B. Sporn, K.L. Gabrielson, H.C. Champion, R.M. Tuder, T.W. Kensler, and S. Biswal Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice Proc. Natl. Acad. Sci. U.S.A. 106 2009 250 255
N.M. Reddy, V. Suryanaraya, M.S. Yates, S.R. Kleeberger, P.M. Hassoun, M. Yamamoto, K.T. Liby, M.B. Sporn, T.W. Kensler, and S.P. Reddy The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice Am. J. Resp. Critic. Care Med. 180 2009 867 874
N. Nagai, R.K. Thimmulappa, M. Cano, M. Fujihara, K. Izumi-Nagai, X. Kong, M.B. Sporn, T.W. Kensler, S. Biswal, and J.T. Handa Nrf2 is a critical modulator of the innate immune response in a model of uveitis Free Radical Biol. Med. 47 2009 300 306
A.E. Nassar, A.M. Kamel, and C. Clarimont Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability Drug Discovery Today 9 2004 1020 1028
J.H. Linand, and A.Y. Lu Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol. Rev. 49 1997 403 449
I.M. Kapetanovic, R. Krishnaraj, T. Martin-Jimenez, L. Yuan, R.B. van Breemen, and A. Lyubimov Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics Chem. Biol. Interact. 164 2006 68 75
